 Broker Wedbush has repeated a neutral stance on biopharma Y-mAbs Therapeutics Inc NASDAQ:YMAB following news that the US Food and Drug Administration FDA has turned down the companys application concerning a treatment for a rare form of nerve cancer in pediatric patients. On December 1, the company that the regulator had issued a complete response letter CRL for the Biologics License Application BLA for the investigational medicine 131I-omburtamab omburtamab to treat CNSleptomeningeal metastasis from neuroblastoma. 